Loading...
Cybin Inc.
CYBN.NE•NEO
HealthcareBiotechnology
CA$10.91
CA$-0.14(-1.27%)
Cybin Inc. (CYBN.NE) Stock Overview
Explore Cybin Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CYBN.NEStats details for CYBN.NE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CYBN.NEAnalyst Recommendations details for CYBN.NE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CEO
Mr. Douglas L. Drysdale
Employees
50
Headquarters
100 King Street West, Toronto, ON
Founded
2020